LP-211 is a drug which acts as a potent and selective agonist at the 5HT7 serotonin receptor, with better brain penetration than older 5-HT7 agonists in the same series, and similar effects in animals.[1][2]

LP-211
Identifiers
  • N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC30H34N4O
Molar mass466.629 g·mol−1
3D model (JSmol)
  • N#Cc3ccc(cc3)CNC(=O)CCCCCN(CC2)CCN2c1ccccc1-c4ccccc4
  • InChI=1S/C30H34N4O/c31-23-25-14-16-26(17-15-25)24-32-30(35)13-5-2-8-18-33-19-21-34(22-20-33)29-12-7-6-11-28(29)27-9-3-1-4-10-27/h1,3-4,6-7,9-12,14-17H,2,5,8,13,18-22,24H2,(H,32,35) ☒N
  • Key:BQEDZLDNNBDKDS-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

See also

edit

References

edit
  1. ^ Hedlund PB, Leopoldo M, Caccia S, Sarkisyan G, Fracasso C, Martelli G, Lacivita E, Berardi F, Perrone R (August 2010). "LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor". Neuroscience Letters. 481 (1): 12–6. doi:10.1016/j.neulet.2010.06.036. PMC 2910240. PMID 20600619.
  2. ^ Monti JM (August 2011). "Serotonin control of sleep-wake behavior". Sleep Medicine Reviews. 15 (4): 269–81. doi:10.1016/j.smrv.2010.11.003. PMID 21459634.